Company: MLTX
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001821586-25-000011
Chunk: 13

Company: MoonLake Immunotherapeutics
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---
,537 — 76 10,613 (10,613)— Buyback of unvested MoonLake AG Common Shares by MoonLake AG into treasury following an employee contract termination (Note 12)— — — — 113 — 1 114 (114)— Capital injection from MoonLake to MoonLake AG (Note 12)— — — — (4,667)— — (4,667)3,057 (1,610)Cancellation of MoonLake Class C Ordinary Shares following an employee contract termination in MoonLake AG (Note 12)— — (16,853)— — — — — — — Issuance of Class A Ordinary Shares, net of transaction costs (Note 12)914,828 — — — 52,540 — — 52,540 — 52,540 Other comprehensive income— — — — — — 257 257 6 263 Net loss for the three months ended March 31, 2024— — — — — (13,673)— (13,673)(302)(13,975)Balance at March 31, 202462,874,637 $6 995,267 $— $670,185 $(130,330)$2,692 $542,553 $9,833 $552,386 

The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

4

MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY(Unaudited)

Class A Ordinary SharesClass C Ordinary SharesAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' EquityNoncontrolling InterestsTotal Equity(in thousands except share data)SharesAmountSharesAmountBalance at January  1, 202563,077,431 $6 841,269 $— $677,415 $(235,593)$4,997 $446,825 $6,566 $453,391 Share-based compensation under the ESPP and Equity Incentive Plan— — — — 2,279 — — 2,279 11 2,290 Conversion of MoonLake Class C Ordinary Shares into Class